EA202090544A1 - Способ лечения заболевания, связанного с tnf- - Google Patents

Способ лечения заболевания, связанного с tnf-

Info

Publication number
EA202090544A1
EA202090544A1 EA202090544A EA202090544A EA202090544A1 EA 202090544 A1 EA202090544 A1 EA 202090544A1 EA 202090544 A EA202090544 A EA 202090544A EA 202090544 A EA202090544 A EA 202090544A EA 202090544 A1 EA202090544 A1 EA 202090544A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tnf
treating
antibody
present
disease related
Prior art date
Application number
EA202090544A
Other languages
English (en)
Russian (ru)
Inventor
Сун Чун Ким
Чжи Хе Сух
Хюн Чул Ан
Сун Ёун Ли
Original Assignee
Селлтрион Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селлтрион Инк. filed Critical Селлтрион Инк.
Publication of EA202090544A1 publication Critical patent/EA202090544A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
EA202090544A 2017-08-30 2018-08-29 Способ лечения заболевания, связанного с tnf- EA202090544A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170110426 2017-08-30
KR20170144521 2017-11-01
KR1020180017449A KR20190024572A (ko) 2017-08-30 2018-02-13 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
PCT/KR2018/009998 WO2019045452A1 (ko) 2017-08-30 2018-08-29 TNFα 관련 질환을 치료하는 방법

Publications (1)

Publication Number Publication Date
EA202090544A1 true EA202090544A1 (ru) 2020-06-05

Family

ID=65801706

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090544A EA202090544A1 (ru) 2017-08-30 2018-08-29 Способ лечения заболевания, связанного с tnf-

Country Status (27)

Country Link
US (2) US20210371510A1 (cg-RX-API-DMAC7.html)
EP (1) EP3677596A4 (cg-RX-API-DMAC7.html)
JP (2) JP7838891B2 (cg-RX-API-DMAC7.html)
KR (3) KR20190024572A (cg-RX-API-DMAC7.html)
CN (1) CN111094342A (cg-RX-API-DMAC7.html)
AR (1) AR135171A2 (cg-RX-API-DMAC7.html)
AU (2) AU2018326037B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020003951A2 (cg-RX-API-DMAC7.html)
CL (1) CL2020000479A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020002117A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200095A (cg-RX-API-DMAC7.html)
CU (1) CU20200015A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2020000049A (cg-RX-API-DMAC7.html)
EA (1) EA202090544A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20014569A (cg-RX-API-DMAC7.html)
GE (2) GEP20237521B (cg-RX-API-DMAC7.html)
IL (1) IL272977A (cg-RX-API-DMAC7.html)
JO (1) JOP20200046A1 (cg-RX-API-DMAC7.html)
MA (1) MA50046A (cg-RX-API-DMAC7.html)
MX (1) MX2020002278A (cg-RX-API-DMAC7.html)
PE (1) PE20200889A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020550066A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202001739YA (cg-RX-API-DMAC7.html)
TW (1) TWI887196B (cg-RX-API-DMAC7.html)
UA (1) UA130480C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019045452A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001927B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
WO2023014992A1 (en) * 2021-08-06 2023-02-09 AndorHealth, LLC Virtual care systems and methods
KR20260087771A (ko) * 2024-12-04 2026-06-12 (주)셀트리온 TNFα 관련 질환을 치료하는 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861335A (en) 1985-07-26 1989-08-29 Duoject Medical Systems Inc. Syringe
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE69319753T2 (de) 1992-11-19 1999-04-15 Tebro S.A., Luxembourg Automatische injektionsvorrichtung für vorgefüllte spritzen
DE4438360C2 (de) 1994-10-27 1999-05-20 Schott Glas Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
TWI439284B (zh) * 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013087914A1 (en) * 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
WO2014114651A1 (en) * 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
EP3078675A1 (en) * 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
KR20170081814A (ko) 2016-01-05 2017-07-13 이경록 헤어 브러시
EP3411401A1 (en) * 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
UA122610C2 (uk) * 2016-06-30 2020-12-10 Селлтріон Інк. Стабільний рідкий фармацевтичний склад

Also Published As

Publication number Publication date
KR102921525B1 (ko) 2026-02-03
JOP20200046A1 (ar) 2020-02-27
JP2024023347A (ja) 2024-02-21
KR20240148776A (ko) 2024-10-11
TWI887196B (zh) 2025-06-21
EP3677596A4 (en) 2021-07-28
IL272977A (en) 2020-04-30
BR112020003951A2 (pt) 2020-09-08
DOP2020000049A (es) 2020-03-15
ECSP20014569A (es) 2020-07-31
JP2020532520A (ja) 2020-11-12
EP3677596A1 (en) 2020-07-08
CO2020002117A2 (es) 2020-04-01
AU2024216469A1 (en) 2024-09-19
MA50046A (fr) 2020-07-08
WO2019045452A1 (ko) 2019-03-07
SG11202001739YA (en) 2020-03-30
TW202521157A (zh) 2025-06-01
CA3074168A1 (en) 2019-03-07
AU2018326037A1 (en) 2020-01-30
PH12020550066A1 (en) 2021-02-15
AR135171A2 (es) 2026-07-08
NZ760588A (en) 2025-05-30
CU20200015A7 (es) 2020-12-17
GEP20237521B (en) 2023-07-25
AU2018326037B2 (en) 2024-06-27
JP7838891B2 (ja) 2026-04-01
PE20200889A1 (es) 2020-09-03
CN111094342A (zh) 2020-05-01
US20210371510A1 (en) 2021-12-02
TW201919697A (zh) 2019-06-01
MX2020002278A (es) 2020-07-13
KR20190024809A (ko) 2019-03-08
UA130480C2 (uk) 2026-03-04
ZA202001927B (en) 2021-08-25
CR20200095A (es) 2020-05-10
KR20190024572A (ko) 2019-03-08
GEAP202315302A (en) 2023-04-10
US20250002573A1 (en) 2025-01-02
CL2020000479A1 (es) 2020-10-02

Similar Documents

Publication Publication Date Title
PH12021550023A1 (en) Humanized anti-tau antibodies
EA201792203A1 (ru) Фармацевтические композиции для комбинированной терапии
EA201791199A1 (ru) Способ лечения болезни альцгеймера
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
EA201890182A1 (ru) Терапевтическое средство для лечения синдрома гунтера и способ его лечения
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
EP2433650A3 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
MX2019014831A (es) Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9.
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
WO2018116267A3 (en) Methods of treatment with anti-factor xi/xia antibodies
PH12020550066A1 (en) METHOD FOR TREATING TNFa-RELATED DISEASE
CY1122508T1 (el) Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου
CL2011002416A1 (es) Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit.
MX2021006457A (es) Anticuerpo inhibidor para usarse para tratar la resistencia severa a la insulina.
EA201892367A1 (ru) Введение биспецифической конструкции, связывающейся с cd33 и cd3, для применения в способе лечения миелоидного лейкоза
NZ754427A (en) Regulation of glucose metabolism using anti-cgrp antibodies
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
PY2013134A (es) Métodos para el tratamiento de enfermedades relacionadas con tnfa
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
BR112023026111A2 (pt) Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
EA201991283A1 (ru) Фармацевтическая композиция для предотвращения опиоидной зависимости
EA202190504A1 (ru) Способы лечения псориаза